This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
In addition to the previously disclosed two deaths, the FDA said in its February...
Kiniksa Pharmaceuticals is stopping development of a midphase autoimmune asset a...
Ryvu Therapeutics is shrinking its headcount by 30% as the Polish biotech focuse...
As always, if you know of layoffs occurring at a biotech, please reach out to th...
With Lava Therapeutics still smoldering from the decision to dump its lead blood...
Takeda has returned to BridGene Biosciences for another small-molecule collabora...
For the last six weeks the shadow of potential layoffs has hung over Repare Ther...
As Alcon Research seeks to block investee Aurion Biotech from listing on the New...
BioCity Biopharma’s selective endothelin receptor type A antagonist has reduced ...
BioCity Biopharma’s selective endothelin receptor type A antagonist has reduced ...
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy cand...
As Alcon Research seeks to block investee Aurion Biotech from listing on the New...
Pfizer has teamed up with Summit Therapeutics to assess whether one of the indus...
Researchers studying a deadly virus discovered a key protein behind its lethalit...
Regeneron’s investigational gene therapy has been tied to notable hearing improv...
After hundreds of FDA employees were suddenly laid off last weekend, including d...
After leaving the FDA, where she served as director of the Center for Drug Evalu...
Pfizer has teamed up with Summit Therapeutics to assess whether one of the indus...
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy cand...
The company said its approach has helped cut the number of discarded livers in h...
The company said its U.S. rollout represents the largest-ever commercial launch ...
Pfizer has teamed up with Summit Therapeutics to assess whether one of the indus...
As OS Therapies prepares to take its bacteria-based cancer asset to the FDA for ...
Sanofi has shared a deeper dive into its 469 million euro bowel disease bet, pub...